Augmedix

Augmedix is a clinical-documentation company that combines AI-driven ambient transcription with a remote human-scribe model. Founded in 2012, the company went public on NASDAQ in 2020 (ticker: AUGX) at a market capitalization that has fluctuated between $50 million and $300 million. In October 2024, Commure (a Sequoia and General Catalyst-backed healthcare-technology platform) announced the acquisition of Augmedix for $139 million in cash, taking the company private and integrating it into Commure's broader healthcare platform.

The company's historical product was a Google Glass-based scribe service in which a remote human scribe (typically based offshore) would listen to a clinician's patient encounters via the wearable and produce notes in real time. As ambient AI matured, Augmedix shifted to a hybrid model — Augmedix Notes uses AI to handle the bulk of the transcription work with human scribes acting as quality reviewers and finishers. The company also offers Augmedix Live (real-time scribe) and Augmedix Go (a fully autonomous AI scribe positioning the company against Abridge and Suki).

Customer deployments span major US health systems including CommonSpirit Health (140+ hospitals nationwide), Sutter Health, Dignity Health, HCA Healthcare, and Houston Methodist. Annual revenue reached approximately $50 million in FY2024, with growth driven by the shift from human-scribe to AI-augmented offerings. Following the Commure acquisition, the Augmedix brand and product line continues but is integrated into Commure's broader healthcare-platform suite.